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infarction (STEMI), non-ST-segment elevation ACS (NSTE-ACS) and
elective patient sand investigated the impact of two-stent procedure.
METHODS From January 2001 to December 2013, percutaneous coro-
nary intervention was performed in 2241 STEMI, 3098 NSTE-ACS, and
13392 elective patients, in whom the incidence of SAT was compared
between those treated with two-stent procedure and single stent pro-
cedure. SATwas deﬁned as stent thrombosis which occurs fromone day
to one month after procedure according to the Academic Research
Consortium deﬁnition. The patients whose cause of stent thrombosis
was diagnosed as heparin-induced thrombocytopenia were excluded.
RESULTS SAT occurred in 12 (0.54%) of the 2241 STEMI patients, 13
(0.42%) of the 3098 NSTE-ACS patients and 35 (0.26%) of the 13392
elective patients. And data are shown in the ﬁgure.
CONCLUSION The incidence of SAT was signiﬁcantly higher in STEMI
patients than in elective patients. The difference was remarkable in
those treated with two-stent procedure but not signiﬁcant in those
treated with single stent procedure.
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BACKGROUND The prognosis of ST-segment Elevation Myocardial
Infarction (STEMI) remains hugely different. Risk stratiﬁcation is
therefore very important for individual patient in terms of prognostic
estimation and medical regiment planning. However, the ways for
stratiﬁcation are far from uniform. Evaluations are made based on
different considerations but largely dependent on doctors’ own expe-
riences. We presumed that a classiﬁcation based on different patho-
physiological stages would be an objective way to stratify patients.
METHODS 140 ﬁrst-STEMI patients were classiﬁed as: grade 0, no
detectable myocardial necrosis; grade 1, with myocardial necrosis;
grade 2, myocardial necrosis with reduced left ventricular ejection
fractions (LVEF); grade 3, reduced LVEF accompanied with cardiac
remodeling; grade 4, apparent mitral regurgitation additional to the
grade-3 criteria. To guarantee the equal comparison, myocardial ne-
crosis, infarction size and cardiac remodeling was determined by
cardiac magnetic resonance while mitral regurgitation and cardiac
improvements were assessed by echocardiography.RESULTS 1.4%, 42.1%, 27.2%, 25% and 4.3% patients were classiﬁed
as grade 0 to grade 4, respectively. According rate of 90-day MACEs
(any death, resuscitated cardiac arrest, acute heart failure and stroke)
was 0%,5.1%, 7.9%, 47.1% and 71.4% (p<0.001). Grade-2 patients had
more LVEF improvements than grade-3/4 patients after 90 days
(44.7% vs 18.4%, p<0.001). Both the classiﬁcation and the infarction
size were independent predictors for 90-day MACEs. However,
without the necessity to quantify infarction extent directly, the clas-
siﬁcation is a good reﬂection of infarction size (00%, 16.789.49%,
24.5310.18%, 36.5913.05% and 40.3315.82% by grade 0 to 4,
P<0.001) and has a comparable prognostic value as the infarction
size(0.822 vs. 0.815, p¼0.855 by C-statistics).
CONCLUSION The new classiﬁcation may provide a standard scale to
describe the impact of STEMI on individual patient and facilitate
diagnostic consensus among doctors.
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BACKGROUND Newer-generation DES may be considered the stan-
dard of care for the treatment of STEMI patients undergoing primary
PCI. However, the implantation of these permanent devices can be
associated with important limitations in this setting. The bio-
resorbable vascular scaffold (Absorb BVS) has been designed to
overcome their limitations, disappearing entirely within 3 years and
restoring native vessel state. In this multicentre prospective registry
we sought to evaluate the immediate and midterm clinical outcomes
following single or multiple overlapping BVS implantation in the
STEMI setting.
METHODS A prospective cohort analysis was performed on all STEMI
patients (symptom onset <24 hours from hospital admission) who
underwent primary PCI with BVS implantation in different Italian
Hospitals. The primary endpoint of the study was procedural success,
deﬁned as BVS implantation at the “culprit” lesion site with less than
30% ﬁnal stenosis and TIMI 3 ﬂow without in-hospital MACE (cardiac
death, myocardial infarction [MI] or need for emergent target lesion
revascularization [TLR]). Furthermore, we evaluated the occurrence
of cardiac death, MI, TLR and BVS thrombosis up to 9-month follow-
up.
RESULTS Between December 2012 and February 2014, 1,232 STEMI
patients underwent primary PCI. Of these, 74 (6.0%) received a BVS,
18 (24.3%) of them were multiple and overlapping. Procedural success
was obtained in 72 (97.3%) cases without differences between the
groups (overlapping BVS100% vs. single BVS 96.4%, p¼0.5). One pa-
tient experienced a re-infarction due to sub-acute BVS thrombosis
while the other patient had a ﬁnal TIMI ﬂow 2. At 9-month follow-up,
2 non-fatal MI (2.7%), 3 TLR (4.1%), and 1 sub-acute BVS thrombosis
were reported in 3 patients (1 [5.6%] overlapping BVS and 2 [3.6%] in
the single BVS group, p¼0.5). All the events were successfully
managed with re-PCI.
CONCLUSION Single or multiple overlapping BVS implantation in
STEMI patients can be successfully performed with a high procedural
success rate and encouraging 9-month outcomes. Larger randomized
trials and longer follow-up are needed to assess the potential clinical
beneﬁt of BVS versus new-generation DES in this setting.
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BACKGROUND Acute myocardial infarction without ST segment
elevation (NSTEMI) is the most common form of presentation of acute
myocardial necrosis. Optimal therapeutic strategy in NSTEMI patients
is a subject of debate – it has been shown recently that disturbed
myocardial perfusion in the non-target coronary arteries is associated
with worse prognosis and potential beneﬁts of expanding the primary
intervention to full instead of target-vessel revascularization are be-
ing discussed. The aim of this study is to compare the incidence of
